Akebia Therapeutics, U.S. Renal Care Announce U.S. Renal Care Kidney Research Proposed To Halt Vafseo Outcomes In Center Experience Study Af
Akebia Therapeutics®, Inc. (Nasdaq: AKBA ), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, and U.S. Renal Care (USRC), the nation’s largest privately held and fastest-growing kidney care provider, are pleased to announce today the decision by USRC Kidney Research